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Abstract
Background: The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and 
the mammalian target of rapamycin (mTOR) kinase is an important mediator for its signaling. Our recent in vitro studies 
suggest that prolonged exposure of pancreatic cancer cells to mTOR inhibitors can promote insulin receptor substrate-
PI3K interactions and paradoxically increase Akt phosphorylation and cyclin D1 expression in pancreatic cancer cells 
(negative feedback loop). The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and 
results in synergistic antitumor activity with erlotinib in preclinical tumor models.
Methods: Two studies prospectively enrolled adult patients with advanced pancreatic cancer, Eastern Cooperative 
Oncology Group performance status 0-1, adequate hematologic, hepatic and renal parameters and measurable 
disease. In Study A, temsirolimus was administered intravenously at 25 mg weekly. In Study B, everolimus was 
administered orally at 30 mg weekly and erlotinib was administered at 150 mg daily. The primary endpoint in both 
studies was overall survival at 6 months. Secondary endpoints included time to progression, progression-free survival, 
overall survival, response rate, safety and toxicity. Pretreatment tumor biopsies were analyzed by immunofluorescence 
and laser scanning cytometry for the expression of pmTOR/mTOR, pAkt/Akt, pErk/Erk, pS6, p4EBP-1 and PTEN.
Results: Five patients enrolled in Study A; Two patients died within a month (rapid disease progression and 
hemorrhagic stroke, respectively). One patient developed dehydration and another developed asthenia. Sixteen 
patients enrolled in Study B.: 12 males, all ECOG PS = 1. Median cycles = 1 (range 1-2). Grade 4 toxicity: hyponatremia (n 
= 1), Grade 3: diarrhea (n = 1), cholangitis (n = 3), hyperglycemia (n = 1), fatigue (n = 1). Grade 2: pneumonia (n = 2), 
dehydration (n = 2), nausea (n = 2), neutropenia (n = 1), mucositis (n = 2) & rash (n = 2). Four patients were hospitalized. 
Progressive disease occurred in 15 and 1 was non-evaluable. Pretreatment biopsies revealed a higher pAkt/Akt ratio in 
tumor specimens that in nonmalignant pancreatic tissue. No such trends were noted for the other biomarkers.
Conclusions: Neither study with mTOR inhibitors demonstrated objective responses or disease stability. The negative 
feedback loop resulting from mTOR inhibition may account for the disease progression and toxicity noted in these 
studies. Future strategies should aim for a broader targeting of the PI3K pathway in pancreatic cancer.
Trial Registration: Trial registration: Study A: NCT 0075647. Study B: NCT00640978
Background
Gemcitabine, the standard frontline chemotherapeutic
agent for advanced pancreatic cancer, was approved by
the Food and Drug Administration (FDA) over a decade
ago. Gemcitabine confers marginal survival benefit,
although one randomized trial reported 'clinical benefit
response' in 24% of patients with advanced pancreatic
cancer [1]. No 'standard' second-line options for treating
this disease have been adopted, although 5-fluorouracil,
capecitabine, or a capecitabine + oxaliplatin combination
is commonly used [2]. Based on our knowledge of pan-
creatic carcinogenesis, molecular targeting may lead to
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Page 2 of 7therapeutic gains in this disease. The epidermal growth
factor receptor (EGFR) and its downstream signaling
intermediates, the mitogen-activated protein kinase
kinase (MEK), extracellular signal-regulated kinase (Erk)
and phosphoinositide 3-kinase (PI3K)/Akt signaling
pathways, play important roles in cellular proliferation,
survival (inhibition of apoptosis) and drug resistance in
pancreatic cancer. We and others have demonstrated that
the PI3K/Akt pathway is constitutively activated in pan-
creatic cancer, thereby activating two important tran-
scription factors, nuclear factor-kappa beta and c-myc
[3].
Although the precise mechanism is unclear, the mam-
malian target of rapamycin (mTOR), a protein kinase, is
the principal mediator of signals arising from PI3K/Akt-
driven mitogen stimulation [4]. Activation of mTOR
involves Akt and the tuberous sclerosis complex. Muta-
tions in these components or in the phosphatase and
tensin homolog (PTEN), a tumor suppressor and negative
regulator of PI3K, may result in their dysregulation and
thus contribute to the pathophysiology of cancer [5]. The
mTOR pathway is also involved in the production of pro-
angiogenic factors, including vascular endothelial growth
factor (VEGF), that enhance endothelial cell growth and
proliferation. Through the activation of its downstream
mediators including the 40S ribosomal S6 kinases, mTOR
can also activate hypoxia-inducible factor 1 (HIF-1). Inhi-
bition of mTOR is therefore being explored as an anti-
cancer strategy for several types of human malignancies,
including pancreatic cancer.
Inhibition of EGFR by its oral tyrosine kinase inhibitor,
erlotinib, has also been shown to have a therapeutic effect
on pancreatic cancer. The results of a recent phase III
clinical trial suggested that erlotinib in combination with
gemcitabine was associated with a significant overall sur-
vival improvement over single-agent gemcitabine [6]. The
sensitivity of cancer cell lines to erlotinib may depend on
the inhibition of the PI3K/Akt pathway. Buck et al. inves-
tigated whether rapamycin, an mTOR inhibitor, could
enhance the sensitivity of non-small-cell lung, pancreatic,
colon and breast cancer cell lines to erlotinib [7]. Erlo-
tinib inhibited Erk, Akt and S6 kinase in only the most
sensitive cancer cell lines. Rapamycin could fully inhibit
S6 kinase in all cell lines but simultaneously activated
Akt. However, the rapamycin/erlotinib combination was
able to down-modulate rapamycin-stimulated Akt activ-
ity. The rapamycin-erlotinib combination resulted in syn-
ergistic cancer cell growth inhibition in vitro and in vivo.
We investigated the role of mTOR inhibition and com-
bined mTOR-EGFR inhibition in pancreatic cancer in the
following two prospective clinical trials: Trial A, a phase
II study of the mTOR-inhibitor, temsirolimus (CCI-779),
and Trial B, a phase II study of the mTOR-inhibitor,
everolimus (RAD001) + erlotinib combination. The dose
of temsirolimus was based on its currently approved dose
for the treatment of renal cancer. The dose of everolimus
+ erlotinib combination was based on a phase I study
conducted at our institution [8].
Methods
Study populations
Eligibility criteria for both studies: adult [Au: >18 years;
metastatic pancreatic adenocarcinoma; Eastern Coopera-
tive Oncology Group (ECOG) performance status 0 or 1;
measurable disease; adequate hematologic, hepatic and
renal function (leukocytes ≥3,000/μl, absolute neutrophil
count ≥1,500/μl, platelets ≥100,000/μl, hemoglobin ≥9 g/
dL, total bilirubin ≤1.5 mg/dl, aspartate aminotransferase
(AST) ≤230 IU/L and alanine aminotransferase (ALT)
≤280 IU/L for subjects with documented liver metastases;
AST ≤115 IU/L and ALT ≤140 IU/L for subjects without
evidence of liver metastases; and creatinine ≤1.5 mg/dl in
men and ≤ 1.2 mg/dl in women). Patients in study B were
required to have received at least one prior gemcitabine-
based regimen. Men and premenopausal women were
advised to use adequate contraception. Prior chemother-
apy or radiation must have been completed at least two
weeks before enrollment.
Excluded from the studies were patients receiving ste-
roids or immunosuppressive medications and those with
hyperlipidemia (cholesterol ≥300 mg/dL and triglycerides
≥ 2.5 × ULN); uncontrolled brain metastases; other
malignancies within the past 3 years, except for ade-
quately treated cervical carcinoma or basal or squamous
cell skin carcinomas; and uncontrolled medical condi-
tions, including cardiorespiratory illness, infectious dis-
eases and bleeding diathesis. Pregnant or nursing women
were also excluded. Immunization with attenuated live
vaccines within one week of study entry or during the
study period was not permitted. Institutional Review
Board approval was obtained for both the studies. All
patients signed an informed consent document.
Treatment
Study A: Patients received 25 mg of temsirolimus once
weekly, infused intravenously over 30 minutes on days 1,
8, 15 and 22. Diphenydramine was also administered at a
dose of 25 mg intravenously 30 minutes prior to infusion.
Study B: Patients received 30 mg of everolimus 30 mg
orally once weekly in combination with 150 mg of erlo-
tinib daily. The treatment cycle lasted 28 days for both
studies. Treatment was continued until disease progres-
sion or unacceptable toxicity. Staging radiological studies
were performed after every 2 cycles. Both were open-
label, single-arm phase II studies conducted at The Uni-
versity of Texas M. D. Anderson Cancer Center. Treat-
ment was administered on an outpatient basis. The
primary outcome measure was overall survival (OS) at 6
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progression (TTP), progression-free survival (PFS),
response rate, safety and toxicity. Response was assessed
by the Response Evaluation Criteria in Solid Tumors
(RECIST) [9].
Dosage Adjustments
Study A: In instances of grade 2 or higher hematologic
toxicity or grade 3 or higher non-hematologic toxicity (as
per National Cancer Institute Common Toxicity Criteria,
version 3.0) related to the study agent, treatment was
withheld until toxicity recovery and then re-initiated with
a 5 mg/week dose reduction; the minimum dose allowed
was 15 mg/week.
Study B: In instances of clinically significant grade 2 or
higher non-hematological toxicities or grade 3 or 4 hema-
tological toxicities, everolimus was interrupted until tox-
icity recovery and re-introduced with a 10 mg dose
reduction. Treatment was discontinued in patients with
recurrent grade 3 or 4 toxicities or treatment interruption
>2 weeks. Doses of erlotinib were reduced in 50-mg dec-
rements; the minimum dose allowed was 50 mg. In
patients with grade 3 or 4 diarrhea, erlotinib was inter-
rupted until resolution and re-introduced with a 50 mg
dose reduction. Rash was treated with topical and/or sys-
temic antibiotics. In those with persistent grade 3 rash,
dosage of erlotinib was reduced as above. Study treat-
ment was discontinued for patients who developed erlo-
tinib-related interstitial lung disease or grade 4 toxicities.
Tissue correlative studies
Core or fine-needle aspiration (FNA) biopsy samples
were used for the correlative studies. In cases where pre-
treatment core biopsy specimens were available, the biop-
sied tissue was analyzed for expression of Kirsten rat
sarcoma viral oncogene homolog (K-ras); PTEN; total
and phosphorylated Erk, Akt and mTOR, pS6K and 4E-
binding protein 1 (P4EBP-1) by immunohistochemistry.
Immunofluorescence staining and Laser Scanning
Cytometry (LSC) were used to quantify the levels of
expression of the above proteins when only FNA samples
were available [10,11]. The LSC system (CompuCyte Cor-
poration, Cambridge, MA) is an automated microscopy
platform that enables the measurement of protein bio-
markers at the resolution of individual cells. The system
uses multiple lasers to measure levels for a panel of pro-
teins (based on conjugated antibody fluorescence) and
provides microscopy for the evaluation of cell morphol-
ogy. The image analysis software automatically enumer-
ates cells based on antibody selection criteria and reports
a sensitive and quantitative measure of protein levels,
termed "mean fluorescence intensity" (MFI). Prior to LSC
analysis, the presence of tumor tissue was confirmed by
light microscopy, and those areas containing tumor were
selected for data acquisition on the LSC system. Each
slide was placed on the motorized microscope stage and
the selected regions were exposed to the scanning laser.
For quantitative measurement of the protein markers,
the contour threshold was set to maximize the contour-
ing of single cells.
To measure the protein markers in this study, we incu-
bated formalin-fixed tissue specimens with rabbit anti-
pS6 antibody (4857, CellSignaling, 1:1000), rabbit anti-
p4EBP-1 antibody (2855, CellSignaling, 1:50), rabbit anti-
PTEN antibody (9559, CellSignaling, 1:100), rabbit anti-
pAKT antibody (124001, Calbiochem, 1:100), mouse
anti-AKT antibody (2966, CellSignaling, 1:50), mouse
anti-pERK antibody (M8159, Sigma, 1:100), rabbit anti-
ERK antibody (442675, Calbiochem, 1:500), rabbit anti-
pmTOR antibody (2976, CellSignaling, 1:50) or rabbit
anti-mTOR antibody (SC-1549, Santa Cruz, 1:50). After
incubation with these antibodies, the specimens were
incubated with the appropriate secondary immunoglobu-
lin G (IgG)-Cy5 conjugate antibody (Jackson ImmunoRe-
search Laboratories, West Grove, PA). Slides were
scanned using a 200× objective and cell nuclei were con-
toured on the basis of the nuclear staining. The relative
fluorescence levels for each antigen were plotted on a
scattergram. The phosphorylated/total ratio of MFIs for
the protein markers was computed.
Statistics
The primary outcome of interest was 6-month survival.
Thall and Simon's method was employed to perform con-
tinuous interim monitoring for efficacy [12]. Phase II data
indicate that patients with gemcitabine-refractory,
advanced pancreatic cancer have a 6-month survival rate
of 29% and a median survival of 3.4 months [13]. This fig-
ure (29% 6-month survival) was referenced to compute
the stopping rule. This prevented a high probability of
stopping if the true success rate was ≥ 20%. The study
would have been stopped at any time if we had deter-
mined there was a less than 1% chance that the surviving
proportion in the experimental arm of the study was less
than that from the historical control group. We assumed
a uniform prior distribution for the surviving proportion
for the new treatment and this distribution was updated
as the study accrued patients. Using this rule, we would
have stopped the study if the surviving proportion was
not greater than 0/10, 1/17, 2/23, 4/33 or 5/38. Computer
simulations were run to determine the operating charac-
teristics of this rule. The probability of early stopping was
99% for a true surviving proportion of 0.05, 88% for a pro-
portion of 0.1, 31% for a proportion of 0.2 and 6% for a
proportion of 0.3. The expression of biomarkers before
treatment was correlated with clinical parameters using
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size, these analyses were exploratory.
Results
Study A enrolled patients from December 2003 through
January 2004. Study B enrolled patients from March 2008
through June 2008. All patients had experienced tumor
progression while receiving gemcitabine prior to enroll-
ment. Table 1 provides patient characteristics.
Study A enrolled 5 patients; 4 actually received the
planned therapy. The study was closed to accrual due to
significant adverse effects (SAEs) resulting from study
treatment. One patient in this study died within 1 month
from rapid disease progression. One died within 1 month
following a cerebrovascular accident; treatment response
could not be evaluated. Two patients were withdrawn
from the study because of SAEs and disease progression.
The median number of treatment cycles was 0.75 (21
days), median OS was 44 days and PFS was 19 days. No
responses occurred. Because of these events, the princi-
pal investigator (HX) recommended stopping the study;
enrollment was stopped and the study closed to accrual.
Study B enrolled 16 patients; 15 received the planned
therapy. The median number of cycles administered was
2 (56 days). PFS was 49 days and the OS was 87 days. No
radiologic responses occurred. After reviewing the sur-
vival data, we concluded that the pre-specified median
OS of 6 months was not likely to be reached and stopped
the study for futility. Tables A2A and B2B depict study-
related toxicities. As shown, systemic toxicities including
fatigue, dehydration, and hyponatremia occurred with
the combination. Lipid profile abnormalities were
uncommon and below grade 2 in severity. Grade 2 skin
rash occurred in 2 patients and was controlled with topi-
cal antibiotics and skin moisturizers.
Correlative data
Figures 1, 2 and 3 show the MFIs of the biomarkers
acquired by LSC as represented in box plots. Activation
of Akt, as assessed by the pAkt/Akt ratio, was noted. No
significant trends were noted in the other biomarkers
studied.
Discussion
The mTOR is a validated target in many human cancers,
and rapamycin analogs (rapalogs) have shown promising
results in various tumor types, including non-Hodgkin's
lymphoma, sarcoma, glioblastoma and endometrial can-
cer. The PI3K/Akt/mTOR pathway is activated in pancre-
atic cancer by overexpression or activation of EGFR and
insulin-like growth factor (IgF1R), by PTEN loss or sec-
ondary to k-ras mutation and activation of the Ras/Raf/
MEK pathway. The investigation of rapalogs for pancre-
atic cancer treatment is therefore based on sound ratio-
nale.
We observed dose-limiting toxicity from standard
doses of temsirolimus in Study A and a lack of antitumor
activity in both studies (A and B). The reason for the tox-
icity noted with standard doses of temsirolimus or
everolimus is not clear. Patients with gemcitabine-refrac-
tory pancreatic cancer can be frail and are often not the
best candidates for aggressive systemic therapy. However,
our institutional experience using capecitabine and oxali-
platin in this patient group reveals that patients with
gemcitabine-refractory pancreatic cancer and good per-
formance status can tolerate and derive benefit from sys-
temic chemotherapy [2]. Therefore, the high toxicity
particularly observed with temsirolimus was surprising,
despite the use of an approved dose. The concern was
raised that the "toxicity" noted resulted at least in part
from disease progression. While this degree of toxicity
did not occur in Study B, the study was discontinued after
enrolling 15 patients, because of disease progression in all
patients.
Table 1: Patient Characteristics (Study A and B)
Characteristic Number
Age 63 (range 34-75)
ECOG PS 0* 3











* ECOG PS: Eastern Co-operative Oncology Group Performance 
Status
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dosing schedule identified in our phase I study. Taberbero
et al. suggest that daily dosing of everolimus may result in
a more sustained inhibition of S6 kinase than intermittent
dosing [14]. However, Wolpin et al, recently reported no
clinically relevant anti-tumor effect in a recent phase II
trial of daily everolimus for patients with advanced, gem-
citabine-refractory pancreatic cancer [15]. Therefore, we
do not believe that the schedule of everolimus used in
Study B resulted in the absence of antitumor effect.
Our recent studies revealed that mTOR inhibitors such
as rapamycin and temsirolimus increase Akt phosphory-
lation/activation and cyclin D1 expression levels in pan-
creatic cancer cells [16]. Similar results were reported by
Wan et al., who suggested that mTOR inhibitors might
eventually promote cellular proliferation and survival if
Table 2: Study A; Number of Patients with Treatment-
Related Toxicities and Study B; Number of Patients with 
Treatment-Related Toxicities
A
Toxicities Grade 3 or 4 Grade 5
Study A





Deep vein thrombosis 1 -
B











Figure 1 Protein Expression by Immunofluorescence. Pretreat-
ment biopsies revealed increased pAkt/Akt ratio in tumor specimens 
as compared with non malignant pancreatic tissue. No such trends 




Figure 2 Mean fluorescence intensity (MFI) of the biomarkers by 
laser scanning cytometry (LSC). For each biomarker, the box repre-
sents the middle half of the distribution of the data points stretching 
from the 25th to the 75th percentile. The line across the box represents 
the median. The lengths of the lines above and below the box are de-
fined by the maximum and minimum data point values, respectively.
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possibility, pancreatic cancer cells were observed by Wan
et al to become more resistant to the mTOR inhibitors
beyond 72-96 hours of continuous treatment in vitro. Li
et al, also observed that the phosphorylation of IRS-1 on
Ser612, a modification that likely inhibits IRS-PI3K inter-
actions, was abolished by rapamycin and CCI-779. It is
therefore conceivable that IRS-Ser612 is a mTOR-regu-
lated site that is part of a negative feedback loop, and that
mTOR inhibitors enhance pAkt levels in pancreatic can-
cer cells by blocking its phosphorylation [18]. Why this
feedback loop is more relevant in pancreatic cancer than
in other cancer types is unclear at this time. Whether the
paradoxical Akt activation secondary to mTOR inhibition
led to the increased toxicity or rapid tumor progression
in Study A cannot be stated with any degree of certainty
as no post-treatment biopsies were performed.
The sensitivity of cancer cell lines to erlotinib depends
at least partially on the inhibition of the PI3K/Akt/mTOR
pathway. The erlotinib-rapamycin combination was
found to have a synergistic cytocidal effect and erlotinib
alone could inhibit rapamycin-induced Akt activation in
non-small cell lung cancer cell lines [19]. These data sup-
ported the investigation of the erlotinib-everolimus com-
bination in Study B. However, in Study B, we observed
neither clinically significant antitumor activity nor dis-
ease stability. One possible explanation may be that most
pancreatic cancers are k-ras mutated, which may induce
baseline Akt activation in pancreatic cancer. Indeed our
pretreatment biopsies revealed an elevated pAkt/Akt
ratio in pancreatic cancer cells pre-treatment. It must be
noted however, that both studies did not include post-
treatment biopsies; therefore, we cannot definitively rule
out an erlotinib effect on Akt activation. One can hypoth-
esize, based on our results, that Akt inhibition as a thera-
peutic strategy for pancreatic cancer should include the
simultaneous inhibition at several points along the PI3K
pathway. Ongoing studies are investigating mTOR inhibi-
tors in combination with IgF1-R or direct Akt antago-
nists.
Standard second-line chemotherapy regimens for
advanced pancreatic cancer at the present time include
oxaliplatin with fluoropyrimidines or capecitabine [2].
Clinical trials that are based on molecular profiling, or
which include one of the above standard regimens should
be encouraged.
Conclusions
PI3K inhibition may be an important therapeutic strategy
for pancreatic cancer. However, we did not observe a clin-
ically relevant anti-tumor effect with the mTOR inhibitor
temsirolimus or with the everolimus + erlotinib combina-
tion.
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